ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Climate Impact & Sustainability Data (2023)
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:1639.62 tCO2e/year
Scope 1 Emissions:5.1 tCO2e/year
Scope 2 Emissions:1634.52 tCO2e/year
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:2342.04 kWh in '000s/year
Water Consumption:4670.00 tonnes/year
Waste Generated:14.48 tonnes/year
Carbon Intensity:Not disclosed
ESG Focus Areas
- Innovative R&D
- Quality management and control
- Intellectual property protection
- Occupational health and safety
- Supply chain management
- Employee training and development
- Corporate governance
- Information system management
- Operational compliance
- Data privacy protection
- Emissions management
- Cooperation and development
- Employee benefits
- Energy utilization
- Anti-corruption
- Employment compliance, equity, and diversity
- Public welfare
- Climate change management
Environmental Achievements
- Implemented energy-saving measures resulting in maintaining previous energy consumption levels while implementing further energy saving and emission reduction.
- Wastewater discharge pollutant concentration met the requirements of Pollutant Emission Standards for Biopharmaceutical Industry (DB31/373–2010), and LAS met the tertiary standard of Shanghai’s Comprehensive Wastewater Emission Standards (DB31/199– 2018).
Social Achievements
- Organized four occupational health trainings with no occupational disease incidents.
- Maintained an employee turnover rate of 12%.
Governance Achievements
- Established a “Zero Tolerance” policy to corruption, developing systems including the Anti-fraud Management Policy, the Anti-money Laundering Management Policy, and the Misconduct Reporting and Investigation Management Policy.
- Conducted compliance training sessions on trade secret protection, intellectual property-related risk prevention in procurement, and other topics.
Climate Goals & Targets
Long-term Goals:
- Not disclosed
Medium-term Goals:
- Not disclosed
Short-term Goals:
- Not disclosed
Environmental Challenges
- Not disclosed
Mitigation Strategies
- Not disclosed
Supply Chain Management
Supplier Audits: On-site audits of new culture media suppliers in 2023
Responsible Procurement
- Procurement Management Regulations, Office Supplies Procurement Management Measures, and Services Procurement Management Measures
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: Appendix C2, the Environmental, Social and Governance Reporting Guide to the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited
Certifications: Null
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- The 2nd Biotech Innovation 50 Companies List
- The 7th Future Healthcare 100 Main List — China Innovative Biomedical List — 7th place in 2023
- Zhangjiang Life & Health Industry Emerging Company of the Year
- 2023 Influential Science and Innovation Enterprise of the Year